The article explores the efforts of legislators in the U.S. to help advance cancer treatment options as of June 2018, highlighting the impact of laws on biosimilar approvals. It offers information on biosimilars which are clinically and cost effective as a generic equivalent for biologic agents. Also discussed are the approved oncology biosimilars, the Food and Drug Administration's support for health providers and the advances in biologics.